1.Continuous glucose monitoring-derived time in range and CV are associated with altered tissue characteristics of the carotid artery wall in people with type 2 diabetes.
Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, Shiraiwa T, Kurozumi A, Taya N, Wakasugi S, Sato F, Ishii R, Gosho M, Shimomura I, Watada H. Diabetologia (IF: 10.12; Q1). 2023 Dec;66(12):2356-2367. 

2.Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study.
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Yasuda T, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H. Sci Rep (IF: 4.38; Q1). 2023 Sep 5;13(1):14649.

3.Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia.
Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Douguchi S, Ofuchi K, Katoh M. Diabetes Metab Syndr Obes (IF: 3.17; Q3). 2023 Jun 20;16:1799-1808.

4.Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Osonoi T, Shirabe S, Saito M, Hosoya M, Douguchi S, Ofuchi K, Katoh M. Front Pharmacol (IF: 5.81; Q1). 2023 Jun 7;14:1205021.

5.Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Kurozumi A, Hatazaki M, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Kato K, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Cardiovasc Diabetol (IF: 7.33; Q1). 2023 Jun 22;22(1):143. 

6.Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Osonoi T, Saito M, Hosoya M, Douguchi S, Ofuchi K, Katoh M. Front Endocrinol (Lausanne) (IF: 5.55; Q1). 2023 Jan 11;13:1042061.